Cellectar Reports 8-Year Complete Response With Iopofosine I 131; Stock Up
Cellectar Biosciences (CLRB) reported a case study where Iopofosine I 131 achieved an 8-year complete response in a DLBCL patient. The treatment led to full resolution of the targeted lesion. CLRB is advancing the drug for another blood cancer and expects to start a Phase 3 study in Q1 2027. The stock was up 5.79% in pre-market trading.
How this was made
The 30-second read
Why it matters
The 8‑year complete response provides compelling proof‑of‑concept, potentially accelerating investor interest and funding for upcoming trials.
Market read
First public disclosure of long‑term efficacy data for a micro‑cap oncology candidate; could move CLRB stock modestly.
What to watch
the drug is still early‑stage; regulatory timeline and competition could temper upside
Background
Cellectar Biosciences (CLRB) is developing Iopofosine I‑131, a radiopharmaceutical targeting B‑cell cancers, with a Phase 3 trial slated for 2027.
Ticker impact
Cellectar Biosciences reported a single-patient case study showing an 8‑year complete response to Iopofosine I‑131 in aggressive DLBCL.
likely upward pressure as market prices in the long‑term efficacy signal
First disclosure of such durable data for a micro‑cap oncology asset; no comparable data previously public.
Market effects
may raise interest in radiopharmaceuticals and B‑cell lymphoma pipelines
limited to US biotech investors
minor, confined to niche oncology investors
Counterpoint
single‑patient data is anecdotal; larger trials may not replicate durability, so price could be overstated
Key entities
- companyCellectar Biosciences, Inc.
US‑listed biotech developing Iopofosine I‑131
